PP
RARE icon

PDT Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

PDT Partners’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$323K Sell
15,405
-161,408
-91% -$3.63M 0.02% 459
2025
Q4 		$4.07M Buy
176,813
+20,120
+13% +$662K 0.26% 137
2025
Q3 		$4.71M Hold
156,693
– – 0.3% 114
2025
Q2 		$5.7M Buy
156,693
+51,772
+49% +$1.87M 0.32% 81
2025
Q1 		$3.8M Buy
104,921
+56,062
+115% +$2.33M 0.27% 118
2024
Q4 		$2.06M Sell
48,859
-17,334
-26% -$860K 0.18% 197
2024
Q3 		$3.68M Buy
66,193
+13,718
+26% +$699K 0.33% 71
2024
Q2 		$2.16M Buy
52,475
+1
+0% +$43 0.2% 186
2024
Q1 		$2.45M Buy
52,474
+4,973
+10% +$235K 0.23% 153
2023
Q4 		$2.27M Buy
47,501
+14,272
+43% +$553K 0.25% 125
2023
Q3 		$1.18M Hold
33,229
– – 0.15% 236
2023
Q2 		$1.53M Buy
+33,229
New +$1.54M 0.21% 169
2021
Q3 		– Sell
-12,129
Closed -$1.16M – 883
2021
Q2 		$1.16M Buy
+12,129
New +$1.26M 0.08% 350

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

PDT Partners's RARE Position: Q1 2026 in Review

PDT Partners reduced its Ultragenyx Pharmaceutical (RARE) stake by 91% in Q1 2026, selling an estimated $3.63M and leaving 15,405 shares worth $323K. The position accounts for 0.02% of the portfolio, ranked #459.

PDT Partners first reported a position in RARE in Q2 2021 and has held it in 13 quarters since. The position peaked at $5.7M in Q2 2025. 296 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • PDT Partners held 15,405 shares of Ultragenyx Pharmaceutical worth $323K as of Q1 2026.
  • PDT Partners sold 161,408 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $3.63M.
  • Ultragenyx Pharmaceutical made up 0.02% of PDT Partners's portfolio in Q1 2026, its #459 holding.
  • PDT Partners first reported a position in Ultragenyx Pharmaceutical in Q2 2021 and has held it in 13 quarters since.
  • PDT Partners's Ultragenyx Pharmaceutical position peaked at $5.7M in Q2 2025.
  • 296 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on PDT Partners's 13F filing for Q1 2026, filed 15 May 2026.